BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/29/2026 8:41:41 AM | Browse: 1 | Download: 11
 |
Received |
|
2026-01-15 03:37 |
|
Peer-Review Started |
|
2026-01-15 03:38 |
|
First Decision by Editorial Office Director |
|
2026-02-02 09:07 |
|
Return for Revision |
|
2026-02-02 09:07 |
|
Revised |
|
2026-02-09 19:48 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-03-09 02:39 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-09 10:03 |
|
Articles in Press |
|
2026-03-09 10:03 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-05-20 01:11 |
|
Publish the Manuscript Online |
|
2026-05-29 08:41 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Surgery |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Induction therapy as a long-term commitment: Lessons from comparative outcomes of alemtuzumab and basiliximab
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Luca Galassi, Erica Altamura, Lina Azzahrani, Federica Facchinetti and Matteo Lino Ravini |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Luca Galassi, Lecturer, MD, Researcher, Postgraduate School of Vascular and Endovascular Surgery, University of Milan, Festa del Perdono Street, Milan 20122, Lombardy, Italy. luca.galassi@unimi.it |
| Key Words |
Kidney transplantation; Induction therapy; Alemtuzumab; Basiliximab; Graft survival; Immunological debt; Precision medicine; Patient safety |
| Core Tip |
The choice of induction therapy in kidney transplantation has commonly been centered around short-term rejection outcomes, which do not reliably predict the long-term safety and graft outcomes. Evidence reveals that, despite similar rejection rates, alemtuzumab is associated with increased risks of infection and malignancy and reduced graft survival among standard-risk recipients. These data support a risk-stratified approach to induction therapy, advocating non-lymphocyte-depleting agents for standard-risk patients and reserving lymphocyte-depleting induction for selected high-risk recipients. |
| Publish Date |
2026-05-29 08:41 |
| Citation |
Galassi L, Altamura E, Azzahrani L, Facchinetti F, Ravini ML. Letter to the Editor: Induction therapy as a long-term commitment: Lessons from comparative outcomes of alemtuzumab and basiliximab. World J Transplant 2026; 16(2): 118962 |
| URL |
https://www.wjgnet.com/2220-3230/full/v16/i2/118962.htm |
| DOI |
https://dx.doi.org/10.5500/wjt.v16.i2.118962 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
